MAIDA, Ivana
 Distribuzione geografica
Continente #
EU - Europa 3.880
NA - Nord America 3.700
AS - Asia 1.954
OC - Oceania 15
SA - Sud America 13
Continente sconosciuto - Info sul continente non disponibili 12
AF - Africa 7
Totale 9.581
Nazione #
US - Stati Uniti d'America 3.671
IT - Italia 1.429
CN - Cina 1.020
UA - Ucraina 920
SG - Singapore 537
FR - Francia 417
DE - Germania 366
HK - Hong Kong 281
SE - Svezia 259
FI - Finlandia 157
IE - Irlanda 96
GB - Regno Unito 79
CZ - Repubblica Ceca 38
KR - Corea 32
CA - Canada 28
BE - Belgio 25
NL - Olanda 20
IR - Iran 18
IN - India 17
PL - Polonia 17
AU - Australia 15
RU - Federazione Russa 14
TR - Turchia 14
EU - Europa 11
CH - Svizzera 9
AE - Emirati Arabi Uniti 7
JP - Giappone 6
HU - Ungheria 5
AT - Austria 4
BG - Bulgaria 4
BR - Brasile 4
IL - Israele 4
VN - Vietnam 4
AR - Argentina 3
LT - Lituania 3
RO - Romania 3
SA - Arabia Saudita 3
CL - Cile 2
ES - Italia 2
ID - Indonesia 2
KE - Kenya 2
KW - Kuwait 2
KZ - Kazakistan 2
NG - Nigeria 2
NO - Norvegia 2
PE - Perù 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AL - Albania 1
BY - Bielorussia 1
DK - Danimarca 1
EC - Ecuador 1
HR - Croazia 1
IQ - Iraq 1
IS - Islanda 1
LU - Lussemburgo 1
MA - Marocco 1
MD - Moldavia 1
MK - Macedonia 1
ML - Mali 1
MY - Malesia 1
NP - Nepal 1
PA - Panama 1
PK - Pakistan 1
PT - Portogallo 1
SI - Slovenia 1
SK - Slovacchia (Repubblica Slovacca) 1
TW - Taiwan 1
UG - Uganda 1
VE - Venezuela 1
Totale 9.581
Città #
Chandler 913
Jacksonville 556
Singapore 445
Princeton 332
Hong Kong 276
Nanjing 253
Dearborn 187
Wilmington 124
Rome 115
Shanghai 108
New York 107
Nanchang 103
Boardman 99
Sassari 98
Ann Arbor 97
Dublin 96
Milan 82
Beijing 74
Shenyang 73
Naples 52
Woodbridge 50
Hebei 48
Changsha 45
Tianjin 44
Santa Clara 40
Andover 37
Brno 37
Helsinki 36
Jiaxing 36
Munich 35
Jinan 34
Seoul 30
Hangzhou 28
Ningbo 28
Ashburn 26
Florence 26
Brussels 25
Zhengzhou 25
Norwalk 24
Turin 23
Kunming 22
Toronto 22
Bologna 17
Ardabil 15
San Francisco 15
San Mateo 15
Leawood 14
Guangzhou 13
Dallas 12
Taizhou 12
Palermo 11
Bari 10
Mountain View 10
Verona 10
Auburn Hills 9
Brescia 9
Izmir 9
Monmouth Junction 9
Nuremberg 9
Augusta 8
Lanzhou 8
Frankfurt am Main 7
Genoa 7
Washington 7
Catania 6
London 6
Napoli 6
Padova 6
Ravenna 6
Rivalta di Torino 6
Venice 6
Amsterdam 5
Budapest 5
Changchun 5
Cosenza 5
Huskvarna 5
Los Angeles 5
Pisa 5
Romola 5
Sydney 5
Tokyo 5
Cagliari 4
Cernusco sul Naviglio 4
Hanoi 4
Hefei 4
Iesi 4
Monza 4
Novara 4
Ottawa 4
Salzano 4
Shenzhen 4
Taranto 4
Barbianello 3
Canberra 3
Cergy 3
Corridonia 3
Desio 3
Fuzhou 3
Genova 3
Haifa 3
Totale 5.307
Nome #
CASE REPORT: MIOCARDITE ACUTA DA CITOMEGALOVIRUS IN GIOVANE PAZIENTE IMMUNOCOMPETENTE 1.322
Use of Cefiderocol in Adult Patients: Descriptive Analysis from a Prospective, Multicenter, Cohort Study 101
Ebola virus disease: Case management in the Institute of Infectious Diseases, University Hospital of Sassari, Sardinia, Italy. 89
Aspetti epidemiologici sulla colonizzazione da Streptococcus agalactiae nelle donne in gravidanza. 89
Activation of MSRV-type endogenous retroviruses during infectious mononucleosis and Epstein-Barr virus latency: the missing link with multiple sclerosis? 82
Antibiotic resistant H-pylori are extremely common in Sardinia. 81
Utilizzo della metodologia bayesiana per lo studio della variazione geografica del rischio in epidemiologia. 80
Incidence of neutropenia and infections during combination treatment of chronic hepatitis C with pegylated interferon alfa-2a or alfa-2b plus ribavirin 79
Strategie di sorveglianza attiva e networking per il controllo delle infezioni da L. monocytogenes 79
Activation of the potentially neuropathogenic HERV-W/MSRV-type endogenous retroviruses during severe infectious mononucleosis and past Epstein-Barr virus infection: the missing link with multiple sclerosis? 79
Approccio molecolare nello studio di un episodio infettivo ospedaliero da Pseudomonas aeruginosa 75
Kaposi's sarcoma herpes virus and Kaposi's sarcoma in the elderly populations of 3 Mediterranean islands. 75
HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels. 73
Listeria monocytogenes meningoencephalitis: molecular methods for diagnosis and for monitoring the response to chemotherapy 71
Approccio molecolare nella diagnosi della tubercolosi umana 71
Accertamento diagnostico di meningoencefalite da Listeria monocytogenes mediante PCR in soggetti immunocompetenti 71
Autoimmune hepatitis induced by pegylated interferon in an HIV-infected patient with chronic hepatitis C 69
Andamento della parotite epidemica nell’Azienda USL n.1 di Sassari e considerazioni sulle strategie vaccinali 68
Antiretroviral-associated portal hypertension: a new clinical condition? Prevalence, predictors and outcome 68
Mucocutaneous leishmniasis as presentation of HIV infection in Sardinia, insular Italy 67
Analisi del case-mix ospedaliero. Il controllo dei ricoveri outlier 67
Surveillance of Poliomyelitis in Italy: immunity status of population against polio and environmental circulation of Poliovirus. General illustration of the results 66
Andamento delle infezioni nosocomiali nel complesso chirurgico Università- Azienda USL n. 1- Sassari. 65
Genetic determinants in critical domains of NS5A are associated with genotype 1b HCV-induced hepatocellular carcinoma 65
Associazione sierologia tra HIV e Trichomonas vaginalis nella popolazione femminile del Nord-Sardegna. 65
Genotypic characterization of clarithromycin-resistant Helicobacter pylori strains 64
Multiclass HCV resistance to interferon-free direct acting antivirals regimens in real life failures advocates for tailored second-line therapies 64
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study 64
OPERA: use of pegylated interferon plus ribavirin for treating hepatitis C/HIV co-infection in interferon-naive patients. 64
HIV related aneurisms 64
Use of pegylated interferons is associated with an increased incidence of infections during combination treatment of chronic hepatitis C: a side effect of pegylation? 61
Caratteristiche cliniche e risposta alla terapia anti-HCV nei soggetti HIV-HCV coinfetti con livelli persistentemente normali di ALT 61
Analisi dell'attività dei C.I.O. in ambito regionale e proposta di un modello organizzativo - funzionale 61
Valutazione della qualità delle schede di dimissione ospedaliera 61
Triple combination therapy for hepatitis C with telaprevir exhibits greater early antiviral activity than with boceprevir. 61
First HAART in HIV-infected patients with high viral load: value of HIV RNA levels at 12 weeks to predict virologic outcome 60
Cytopenias during treatment of HIV-HCV-coinfection with pegylated interferon and ribavirin: safety analysis of the OPERA study. 60
Episodes of low-level viral rebound in HIV-infected patients on antiretroviral therapy: frequency, predictors and outcome 60
Profile of patients triply infected with HIV and the hepatitis B and C viruses in the HAART era 60
Visceral Leishmaniasis and Pegylated Interferon. Author’s reply 59
Prevalence of Single and Multiple Natural NS3, NS5A and NS5B Resistance-Associated Substitutions in Hepatitis C Virus Genotypes 1-4 in Italy 59
DNMT1 modulation in chronic hepatitis B patients and hypothetic influence on mitochondrial DNA methylation status during long-term nucleo(t)side analogs therapy 59
Aspetti epidemiologici di infezioni gastroenteriche in paesi in via di sviluppo 59
Long-term follow-up of HIV-infected patients with chronic hepatitis C virus infection treated with interferon-based therapies 58
Characteristics and Prospects for Hepatitis C Therapy of an HIV-HCV Coinfected Population Followed at a Reference HIV Center 58
Differences in liver fibrosis and response to pegylated interferon plus ribavirin in HIV/HCV-coinfected patients with normal vs elevated liver enzymes 58
Predictors of Virological Response to Atazanavir in Protease Inhibitor-Experienced Patients 57
Clonal relationships among Salmonella enteritidis phage type 3 outbreak isolates traced by DNA fingerprinting 57
Resistance-guided retreatment of HCV infected patients with a previous failure to an NS5A inhibitor-containing regimen: Italian real life experience 57
Simplification From Protease Inhibitors to Once- or Twice-Daily Raltegravir: The ODIS Trial 57
QuantiFERON TB Gold: a new method for latent tuberculosis infection 57
The changing face of the HIV epidemic in Northern Sardinia: increased diagnoses among pregnant women 57
Monitoraggio di metalli pesanti nelle acque costiere della Sardegna settentrionale mediante utilizzo di indicatori biologici 56
New paradigms in the management of HIV and hepatitis C virus coinfection 56
Predictors of Hepatitis C Treatment Failure After Using Direct-Acting Antivirals in People Living With Human Immunodeficiency Virus 56
Higher Risk of Hyperglycemia in HIV-Infected Patients Treated with Didanosine Plus Tenofovir 55
Triple-nucleoside regimens versus efavirenz 55
Clonal relations among Salmonella enteritidis phage type 3 outbreak isolates traced by DNA fingerprinting 55
Lysteria monocytogenes meningoencephalitis: molecular methods for diagnosis and for monitoring the response to chemotherapy 55
alpha-and gamma-tocophetol modulate the apoptotic signaling induced by oxidized low-density lipoprotein in human coronaric smooth muscle cells 55
HIV-related aneurysms 54
Hepatotoxicity of Antiretroviral Drugs Is Reduced after Successful Treatment of Chronic Hepatitis C in HIV-Infected Patients 53
Multiclass hepatitis C virus resistance to direct acting antivirals in real life interferon-free regimens failures advocates for tailored second-line therapies 53
Dalbavancin two dose regimen for the treatment of prosthetic joint infections: new possible options for difficult to treat infectious diseases 53
Correlates of HIV, HBV, and HCV infection in a prison inmate population: Results from a multicentre study in Italy 53
Switch from ritonavir-boosted to unboosted atazanavir guided by therapeutic drug monitoring 53
Hepatitis C Viremia in HIV/HCV-Coinfected Patients: Lower Levels in Presence of Chronic Hepatitis B 52
Severe liver disease associated with prolonged exposure to antiretroviral drugs 52
Liver fibrosis in patients with chronic hepatitis C and persistently normal liver enzymes: influence of HIV infection. 52
Rapid detection and identification of Mycobacterium tuberculosis by Real Time PCR and Bactec 960 MIGT 51
Safety and efficacy of direct-acting antivirals in transfusion-dependent thalassemic patients with chronic hepatitis C 51
Serum homocysteine levels are increased in women with gestational diabetes mellitus 51
Does Angiotensin II receptor blockers increase the risk of SARS-CoV-2 infection? A real-life experience 51
Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies 51
Database per il monitoraggio del rischio professionale negli operatori sanitari 51
Hepatitis C virus-RNAclearance in HIV-coinfected patients with chronic hepatitis C treated with pegylated interferon plus ribavirin 51
Upper Gastrointestinal Bleeding May Unmask Didanosine-Associated Portal Hepatopathy in HIV/HCV Co-infected Patients 50
Does counselling increase sustained benefit of HAART among prison inmates after release to the community? 50
Impiego degli antibiotici in un DRG chirurgico specialistico e verifica dei costi 50
Inquinamento ambientale nelle sale operatorie. Nota II: condizioni microclimatiche e microbiologiche 50
Liver Fibrosis Stage and HCV Genotype Distribution in HIV-HCV Coinfected Patients with Persistently Normal Transaminases 49
Severe portal hypertension not associated to cirrhosis in HIV+ patients 49
PREVENTION OF TRAVEL ASSOCIATED INFECTION DUE TO LEGIONELLA: MICROBIOLOGIC ANALYSIS IN LINERS AND CRUISE SHIPS 49
Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: What are the chances for second-line regimens? 49
Database per il monitoraggio del rischio professionale negli operatori sanitari 48
Unexplained severe portal hypertension in HIV-infected patients: a new clinical entity? 48
Rickettsia monacensis as Cause of Mediterranean Spotted Fever-like Illness, Italy 48
Complications in treating chronic hepatitis B in patients with HIV 48
Hepatic peroxisome proliferator-activated receptor γ and α-mRNA expression in HCV-infected adults is decreased by HIV co-infection and is also affected by ethnicity 48
Severe liver disease of unknown origin in HIV-infected patients 47
Liver transplantation in HIV-HCV coinfected candidates: What is the most appropriate time for evaluation? 47
MOLECULAR APPROACH IN THE DIAGNOSIS OF HUMAN TUBERCULOSIS 47
Distinct hepatitis C virus kinetics in HIV-infected patients treated with ribavirin plus either pegylated interferon alpha2a or alpha2b 47
Liver Enzyme Elevation in Hepatitis C Virus (HCV)-HIV-Coinfected Patients Prior and After Initiating HAART: Role of HCV genotypes 46
Non cirrhotic portal hypertension in HIV-infected patients 45
Severe portal hypertension in HIV patients with no primary liver disease: prevalence, histology and potential etiology 45
Very late HCV relapse following triple therapy for hepatitis C. 44
Caratterizzazione molecolare di stipiti di P. aeruginosa isolati in un reparto ad alto rischio 44
Modulation by α- and γ-tochopherol and oxidized low density lipoprotein in human coronaric smooth muscle cells 44
HPV infection in HIV-positive females: the need for cervical cancer screening including HPV-DNA detection despite successful HAART 44
Totale 7.145
Categoria #
all - tutte 50.549
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 50.549


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020865 0 0 0 0 0 0 290 70 187 141 163 14
2020/20211.485 165 9 212 15 155 82 164 16 244 230 138 55
2021/2022965 152 27 24 46 18 19 45 67 77 32 110 348
2022/20231.962 199 101 39 314 190 334 21 222 331 25 108 78
2023/2024930 105 62 32 41 193 96 27 52 16 57 97 152
2024/20251.451 113 161 376 137 199 197 268 0 0 0 0 0
Totale 9.895